LEADER 03139nam  2200697Ia 450 
001 9910816268703321
005 20200520144314.0
010   $a9786612491269
010   $a9781282491267
010   $a1282491261
010   $a9781444318579
010   $a1444318578
010   $a9781444318586
010   $a1444318586
035   $a(CKB)2550000000006559
035   $a(EBL)480427
035   $a(OCoLC)606871882
035   $a(SSID)ssj0000358524
035   $a(PQKBManifestationID)11305168
035   $a(PQKBTitleCode)TC0000358524
035   $a(PQKBWorkID)10377769
035   $a(PQKB)10427351
035   $a(MiAaPQ)EBC480427
035   $a(Au-PeEL)EBL480427
035   $a(CaPaEBR)ebr10361197
035   $a(CaONFJC)MIL249126
035   $a(Perlego)2756079
035   $a(EXLCZ)992550000000006559
100   $a20090826d2010      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aCritical pathways to success in CNS drug development /$fNeal R. Cutler ... [et al.]
205   $a2nd ed.
210   $aChichester, UK ;$aHoboken, NJ $cWiley-Blackwell$d2010
215   $a1 online resource (273 p.)
300   $aDescription based upon print version of record.
311 08$a9781444330649 
311 08$a1444330640 
320   $aIncludes bibliographical references and index.
327   $aCritical Pathwaysto Success in CNSDrug Development; Contents; Acknowledgments; Foreword; 1 The impending crisis in CNS drug development; 2 Animal models and procedures for CNS disorders; 3 Preclinical antecedents to early human clinical trials; 4 Biomarkers and surrogate markers in drug development; 5 Neuroimaging and cognitive assessments in early drug development; 6 Bridging and CSF studies; 7 A case study from preclinical to early clinical trials; Index
330   $aCovering the latest advances in CNS drug development, this book will guide all those involved in pre-clinical to early clinical trials. The authors describe how recent innovations can accelerate the development of novel CNS compounds, improve early detection of efficacy and toxicity signals, and increase the safety of later-stage clinical trials. The current crisis in the drug development industry is critically reviewed, as well as the steps needed to correct the problems, including new government-backed regulations and industry-based innovations designed to accelerate CNS drug development i
606   $aNeuropsychopharmacology
606   $aDrug development
606   $aCritical path analysis
606   $aCentral nervous system$xEffect of drugs on$xResearch$xMethodology
615  0$aNeuropsychopharmacology.
615  0$aDrug development.
615  0$aCritical path analysis.
615  0$aCentral nervous system$xEffect of drugs on$xResearch$xMethodology.
676   $a615
701   $aCutler$b Neal R$0930110
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910816268703321
996   $aCritical pathways to success in CNS drug development$94044113
997   $aUNINA